基于肠-肝轴探讨荣木复肝方对胆汁淤积小鼠的改善作用OA
Improvement effects of Rongmu Fugan Formula on bile stasis in mice based on gut-liver axis
目的 探讨荣木复肝方改善肝内胆汁淤积(IC)小鼠肠、肝损伤的作用.方法 将60只雄性KM小鼠随机分为空白组(0.1mL/kg生理盐水)、模型组[0.1g/kg α-萘异硫氰酸酯(ANIT)]、奥贝胆酸(10mg/kg奥贝胆酸)组及荣木复肝方低、中、高剂量组(2.8、5.6、11.2 g/kg荣木复肝方).除空白组外,其余各组小鼠于第1天口服ANIT进行造模,连续7 d灌胃相应药物,收集血清、肝脏和回肠.生化法检测血清肝功能(ALT、AST、ALP、TBA、TBIL、DBIL)、脂质(TC、TG、LDL-C、HDL-C)水平,HE染色和AB-PAS染色观察肝和肠组织病理,免疫组化和Western blot法检测回肠和肝组织关键靶蛋白法尼醇X受体(FXR)表达,免疫组化法检测肝组织细胞角蛋白19(CK19)和肠组织闭锁蛋白(Occludin)表达以观察胆管增生反应和肠屏障功能,RT-qPCR法检测胆汁酸转运体表达.结果 与空白组比较,模型组小鼠血清ALT、AST、ALP、TBA、TBIL、DBIL、TC、TG、LDL-C水平升高(P<0.01),HDL-C水平降低(P<0.01);胆管细胞增生,回肠和肝组织病理损伤;回肠组织杯状细胞数和Occludin蛋白表达降低(P<0.01);肝组织CK19蛋白表达升高(P<0.01);肝和回肠组织FXR蛋白表达降低(P<0.01);胆脂酸合成酶表达升高(P<0.01),转运蛋白表达降低(P<0.01).与模型组比较,荣木复肝方可降低小鼠血清ALT、AST、ALP、TBA、TBIL、DBIL、TC、TG、LDL-C 水平(P<0.05,P<0.01),升高 HDL-C 水平(P<0.01);减轻回肠和肝组织病理损伤;升高回肠组织杯状细胞数和Occludin蛋白表达(P<0.05,P<0.01);降低肝组织CK19蛋白表达(P<0.05,P<0.01);升高肝和回肠组织FXR蛋白表达(P<0.05,P<0.01);降低胆脂酸合成酶表达(P<0.01),升高转运蛋白表达(P<0.05,P<0.01).结论 荣木复肝方对IC小鼠肠、肝损伤具有改善作用,其调控机制可能与核受体FXR相关.
AIM To explore the effects of Rongmu Fugan Formula on improving intestinal liver injury in mice with intrahepatic cholestasis(IC).METHODS Sixty male KM mice were randomly divided into blank group(0.1 mL/kg normal saline),model group[0.1 g/kg α-naphthyl isothiocyanate(ANIT)],oberoic acid(10 mg/kg oberoic acid)and Rongmu Fugan Formula low,medium and high dose groups(2.8,5.6 and 11.2 g/kg Rongmu Fugan Formula).Except for the blank group,the other groups of mice were given ANIT on the first day,and then the corresponding drugs were gavaged for 7 days,and the serum,liver and ileum were collected.Levels of serum liver function(ALT,AST,ALP,TBA,TBIL,DBIL)and lipid(TC,TG,LDL-C,HDL-C)were detected by biochemical method.HE staining and AB-PAS staining were used to observe the histopathology of liver and intestine.Immunohistochemistry and Western blot were used to detect the expression of key target protein farnesol X receptor(FXR)in ileal and liver tissues.Immunohistochemmistry was used to detect the expressions of cytokeratin 19(CK19)in liver tissue and Occludin in intestinal tissue,so as to observe the bile duct hyperplasia and intestinal barrier function.RT-qPCR was used to detect the expressions of bile acid transporters.RESULTS Compared with the blank group,the levels of serum ALT,AST,ALP,TBA,TBIL,DBIL,TC,TG and LDL-C in the model group increased(P<0.01),while the HDL-C level decreased(P<0.01).Bile duct cell proliferation and pathological damage in ileal and liver tissues were observed.The number of goblet cells and the expression of Occludin protein in ileal tissues decreased(P<0.01).The expression of CK19 protein in liver tissue increased(P<0.01).The expressions of FXR protein in liver and ileal tissues decreased(P<0.01).The expressions of bile acid synthesis increased(P<0.01)and the expressions of transporters decreased(P<0.01).Compared with the model group,Rongmu Fugan Formula decreased the levels of serum ALT,AST,ALP,TBA,TBIL,DBIL,TC,TG and LDL-C(P<0.05,P<0.01)and increased the HDL-C level(P<0.01).It also alleviated pathological damage in ileal and liver tissues;increased the number of goblet cells and the expression of Occludin protein in ileal tissue(P<0.05,P<0.01);decreased the expression of CK19 protein in liver tissue(P<0.05,P<0.01);increased the expression of FXR protein in liver and ileal tissues(P<0.05,P<0.01).It decreased the expressions of bile acid synthesis(P<0.01)and increased the expressions of transporters(P<0.05,P<0.01).CONCLUSION Rongmu Fugan Formula exerts a protective effect against intestinal and liver injury in IC mice,and its regulatory mechanism may be associated with the nuclear receptor FXR.
徐华明;杨柳;王培育;闫五玲;郑思嘉;杨念;吕晨晓;朱平生;刘延鑫
河南中医药大学医学院,河南郑州 450046||河南中医药大学中医药科学院,河南郑州 450046河南中医药大学中医药科学院,河南郑州 450046河南中医药大学针灸推拿学院,河南郑州 450008河南中医药大学第三附属医院病理科,河南郑州 450008河南中医药大学中医药科学院,河南郑州 450046河南中医药大学中医药科学院,河南郑州 450046河南中医药大学中医药科学院,河南郑州 450046河南中医药大学中医学院,河南郑州 450046河南中医药大学医学院,河南郑州 450046
医药卫生
荣木复肝方胆汁淤积肠-肝轴法尼醇X受体(FXR)胆汁酸代谢
Rongmu Fugan Formulacholestasisgut-liver axisfarnesoid X receptor(FXR)bile acid metabolism
《中成药》 2026 (5)
1478-1485,8
国家自然科学基金面上项目(82074340)河南省中医药科学研究专项重点项目(2024ZY1030)
评论